Inventory, net of related reserves, consisted of the following:


	September 30,		December 31,
(in thousands)	2025		2024
Raw materials	$	24,960	$	29,080
Work in process		15,156		15,870
Finished goods		21,924		23,075
Total inventory, net(1)	$	62,040	$	68,025

(1)

As of September 30, 2025, amounts totaling $3.5 million, $0.1 million and $7.0 million were reclassified to assets held for sale, from raw materials, work in process and finished goods, respectively, as a result of the pending sale of the Company’s single-photon emission computerized tomography (“SPECT”) business. See Note 8, “Assets and Liabilities Held for Sale” for more information.

The majority of the value of the inventory relates to non-radioactive products. With respect to the Company’s products that are radiopharmaceuticals, due to the limited shelf life of such products, they are generally not held as finished goods.